A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
← catalyst calendarNCT05967351 · readout in 2,630 d
Sponsored by Sarepta Therapeutics, Inc. (industry) · SRPT — their whole pipeline →. With Hoffmann-La Roche.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Other
Enrollment
400estimated
Sites
38
Countries
Belgium, Germany, Hong Kong +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-27 | actual | When the study began enrolling |
| Primary completion | 2033-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy
Intervention
- Genetic: delandistrogene moxeparvovec — also filed as SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)
measured Up to 10 years
Permalink · SRPT's whole pipeline · Catalyst calendar · Every registered study · What changed